The FDA approved Leqembi via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Leqembi is the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiology of the disease. These medications represent an important advancement in the ongoing fight to effectively treat Alzheimer’s disease.
Alzheimer’s disease is an irreversible, progressive brain disorder affecting more than 6.5 million Americans that slowly destroys memory and thinking skills and, eventually, the ability to carry out simple tasks.
Leqembi was approved using the Accelerated Approval pathway, under which the FDA may approve drugs for serious conditions where there is an unmet medical need and a drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients.
Eisai, which led the development of Leqembi (lecanemab), is pricing the treatment at $26,500 per year in the U.S. Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, recently announced it has been selected by Eisai as the sole specialty pharmacy distribution partner for Leqembi.
Soleo Health will distribute LEQEMBI to provider offices and infusion centers as well as administer it across its many Ambulatory Infusions Centers (AICs) nationwide, including those owned and operated through its provider division, Virtis Health. The combined service offering of Soleo Health and Virtis Health provides patients with flexible site of care options to meet their individual therapy needs and service expectations in a cost-effective setting.
Soleo Health’s interdisciplinary team comprises highly experienced physician specialists, nurse practitioners, clinical pharmacists, registered nurses, reimbursement specialists and patient care ambassadors collaborating with its referring partners.
Soleo Health optimizes patient access solutions and delivers comprehensive services, leading to quantifiable clinical and economic value, resulting in positive patient experiences. Soleo Health has 22 pharmacy locations with national nursing coverage and pharmacy licensure in 50 states and is accredited by URAC, ACHC with Distinction in Rare Disease and Orphan Drugs and The Joint Commission. Additionally, the Company operates more than 40 infusion centers throughout the U.S.
Takeaway: Patients receiving LEQEMBI will be supported through Soleo Health’s Alzheimer’s Disease Therapeutic Care Management Center (TCMC)